^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
TP53-EphA-2-CAR-DC
i
Other names: TP53-EphA-2-CAR-DC, autologous EphA2-targeting CAR-DC vaccine loaded with TP53 mutant peptide
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Chinese PLA General Hospital
Drug class:
Dendritic cell activator, EphA2 inhibitor
Related drugs:
1year
Combination of CAR-DC Vaccine and ICIs in Malignant Tumors (clinicaltrials.gov)
P1, N=10, Recruiting, Chinese PLA General Hospital | Initiation date: Feb 2023 --> Jul 2023
Trial initiation date • IO biomarker • Metastases
|
TP53 (Tumor protein P53) • IL6 (Interleukin 6) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
|
PD-L1 expression • TP53 mutation • MSI-H/dMMR • TP53 R175H • TP53 R248Q • TP53 R273H
|
Yervoy (ipilimumab) • albumin-bound paclitaxel • cyclophosphamide • TP53-EphA-2-CAR-DC
almost2years
Combination of CAR-DC Vaccine and Anti-PD-1 Antibody in Malignant Tumors (clinicaltrials.gov)
P1, N=10, Recruiting, Chinese PLA General Hospital | N=20 --> 10
Enrollment change • IO biomarker • Metastases
|
TP53 (Tumor protein P53) • IL6 (Interleukin 6) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
|
PD-L1 expression • TP53 mutation • MSI-H/dMMR • TP53 R175H • TP53 R248Q • TP53 R273H
|
albumin-bound paclitaxel • cyclophosphamide • TP53-EphA-2-CAR-DC
almost2years
Combination of CAR-DC Vaccine and Anti-PD-1 Antibody in Malignant Tumors (clinicaltrials.gov)
P1, N=20, Recruiting, Chinese PLA General Hospital
New P1 trial • IO biomarker • Metastases
|
TP53 (Tumor protein P53) • IL6 (Interleukin 6) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
|
PD-L1 expression • TP53 mutation • MSI-H/dMMR • TP53 R175H • TP53 R248Q • TP53 R273H
|
albumin-bound paclitaxel • cyclophosphamide • TP53-EphA-2-CAR-DC
Share via
